US3906092A
(en)
|
1971-11-26 |
1975-09-16 |
Merck & Co Inc |
Stimulation of antibody response
|
US4415732A
(en)
|
1981-03-27 |
1983-11-15 |
University Patents, Inc. |
Phosphoramidite compounds and processes
|
US4373071A
(en)
|
1981-04-30 |
1983-02-08 |
City Of Hope Research Institute |
Solid-phase synthesis of polynucleotides
|
US4401796A
(en)
|
1981-04-30 |
1983-08-30 |
City Of Hope Research Institute |
Solid-phase synthesis of polynucleotides
|
DE3314999A1
(de)
|
1983-04-26 |
1985-03-14 |
Behringwerke Ag, 3550 Marburg |
Verwendung des diterpen-derivates forskolin zur immunstimulation
|
US5663163A
(en)
|
1987-09-07 |
1997-09-02 |
Fujisawa Pharmaceutical Co., Ltd. |
Cephem compounds and processes for preparation thereof
|
CA1320446C
(en)
|
1988-06-20 |
1993-07-20 |
William A. Carter |
Modulation of lymphokine-resistant cellular states by dsrnas
|
JP3150967B2
(ja)
|
1989-10-11 |
2001-03-26 |
エイチイーエム リサーチ,インコーポレイティド |
二本鎖rnaによる損傷に続くショックからの保護
|
JPH08508714A
(ja)
|
1993-01-25 |
1996-09-17 |
ハイブライドン インコーポレイテッド |
オリゴヌクレオチド・アルキルホスホネートおよびアルキルホスホノチオエート
|
WO1994017792A2
(en)
|
1993-01-27 |
1994-08-18 |
Affymax Technologies N.V. |
Compositions and methods for transdermal drug delivery
|
US5516652A
(en)
|
1993-10-06 |
1996-05-14 |
Merck Frosst Canada Inc. |
DNA encoding prostaglandin receptor IP
|
AU704549B2
(en)
|
1994-03-18 |
1999-04-29 |
Lynx Therapeutics, Inc. |
Oligonucleotide N3'-P5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
|
WO1995026204A1
(en)
|
1994-03-25 |
1995-10-05 |
Isis Pharmaceuticals, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
US5874560A
(en)
|
1994-04-22 |
1999-02-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Melanoma antigens and their use in diagnostic and therapeutic methods
|
EP0772619B2
(en)
|
1994-07-15 |
2010-12-08 |
The University of Iowa Research Foundation |
Immunomodulatory oligonucleotides
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US7148205B2
(en)
|
1995-12-13 |
2006-12-12 |
Mirus Bio Corporation |
Intravascular delivery of non-viral nucleic acid
|
US6689757B1
(en)
|
1996-02-12 |
2004-02-10 |
M.L. Laboratories Plc |
Methods for vaccination and vaccines therefor
|
US6090391A
(en)
|
1996-02-23 |
2000-07-18 |
Aviron |
Recombinant tryptophan mutants of influenza
|
BRPI9710363B8
(pt)
*
|
1996-07-15 |
2021-07-06 |
Us Gov Health & Human Serv |
partìcula de vìrus sincicial respirátorio recombinante (rsv) infeccioso atenuado, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante (rsv), vetor de expressão, e, método de produção de um vìrus sincicial respiratório recombinante (rsv) infeccioso.
|
ATE292980T1
(de)
|
1996-10-11 |
2005-04-15 |
Univ California |
Immunostimulierende oligonucleotidekonjugate
|
EP0839912A1
(en)
|
1996-10-30 |
1998-05-06 |
Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) |
Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
|
GB9623051D0
(en)
|
1996-11-06 |
1997-01-08 |
Schacht Etienne H |
Delivery of DNA to target cells in biological systems
|
EP0855184A1
(en)
|
1997-01-23 |
1998-07-29 |
Grayson B. Dr. Lipford |
Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
AU6972798A
(en)
|
1997-04-18 |
1998-11-13 |
University Of Medicine And Dentistry Of New Jersey |
Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
|
EP1374894A3
(en)
|
1997-06-06 |
2004-09-22 |
Dynavax Technologies Corporation |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
CA2291483C
(en)
|
1997-06-06 |
2012-09-18 |
Dynavax Technologies Corporation |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
US20040006034A1
(en)
|
1998-06-05 |
2004-01-08 |
Eyal Raz |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
US6589940B1
(en)
|
1997-06-06 |
2003-07-08 |
Dynavax Technologies Corporation |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
DK1009413T3
(da)
|
1997-09-05 |
2007-06-11 |
Univ California |
Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma
|
US6096307A
(en)
|
1997-12-11 |
2000-08-01 |
A. Glenn Braswell |
Compositions for immunostimulation containing Echinacea angustofolia, bromelain, and lysozyme
|
JP2002510644A
(ja)
|
1998-04-03 |
2002-04-09 |
ユニバーシティ オブ アイオワ リサーチ ファウンデーション |
免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物
|
EP1071472A4
(en)
|
1998-04-23 |
2002-04-17 |
Univ Michigan Technology Man W |
PEPTIDES FOR EFFICIENT GENE TRANSFER
|
AU776268B2
(en)
|
1999-06-08 |
2004-09-02 |
Aventis Pasteur |
Immunostimulant oligonucleotide
|
CA2312385A1
(en)
|
1999-06-22 |
2000-12-22 |
Daiso Co., Ltd. |
Process for producing erythro-3-amino-2-hydroxybutyric acid derivatives
|
US6514948B1
(en)
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
AU6097100A
(en)
|
1999-07-13 |
2001-01-30 |
Regents Of The University Of Michigan, The |
Crosslinked dna condensate compositions and gene delivery methods
|
US20030104622A1
(en)
|
1999-09-01 |
2003-06-05 |
Robbins Paul D. |
Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
|
EP1541690A3
(en)
|
1999-09-09 |
2005-07-27 |
CureVac GmbH |
Transfer of mRNA using polycationic compounds
|
AT409085B
(de)
|
2000-01-28 |
2002-05-27 |
Cistem Biotechnologies Gmbh |
Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
|
US6552006B2
(en)
|
2000-01-31 |
2003-04-22 |
The Regents Of The University Of California |
Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
|
IL151928A0
(en)
|
2000-03-30 |
2003-04-10 |
Whitehead Biomedical Inst |
Rna sequence-specific mediators of rna interference
|
CA2412026A1
(en)
|
2000-06-07 |
2001-12-13 |
Biosynexus Incorporated |
Immunostimulatory rna/dna hybrid molecules
|
AU7013401A
(en)
|
2000-06-22 |
2002-01-02 |
Univ Iowa Res Found |
Methods for enhancing antibody-induced cell lysis and treating cancer
|
DK1292615T3
(da)
|
2000-06-23 |
2007-02-19 |
Wyeth Corp |
Modificerede morbillivirus V-proteiner
|
US6376704B1
(en)
|
2000-06-28 |
2002-04-23 |
3M Innovative Properties Company |
Naphthyoxyalkyl(meth)acrylates with high refractive indices and low glass transition temperatures
|
US6716434B1
(en)
|
2000-09-19 |
2004-04-06 |
Daniel R. Ansley |
Composition and method for immunostimulation in non- mammalian vertebrates
|
GB0025577D0
(en)
|
2000-10-18 |
2000-12-06 |
Smithkline Beecham Biolog |
Vaccine
|
US7371387B2
(en)
|
2001-02-21 |
2008-05-13 |
Genitrix Llc |
Vaccine compositions and methods of modulating immune responses
|
CA2443338A1
(en)
|
2001-04-02 |
2002-10-10 |
University Of South Florida |
Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof
|
ATE376434T1
(de)
|
2001-04-21 |
2007-11-15 |
Curevac Gmbh |
Injektionsgerät für mrna applikation
|
EP2305699B1
(de)
|
2001-06-05 |
2014-08-13 |
CureVac GmbH |
Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose
|
US7785610B2
(en)
|
2001-06-21 |
2010-08-31 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—III
|
JP2005525992A
(ja)
|
2001-06-25 |
2005-09-02 |
イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム |
生物学的物質を充填した小胞の調製法およびそれらの様々な使用
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
DE10148886A1
(de)
|
2001-10-04 |
2003-04-30 |
Avontec Gmbh |
Inhibition von STAT-1
|
US7276489B2
(en)
|
2002-10-24 |
2007-10-02 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
|
WO2003035836A2
(en)
|
2001-10-24 |
2003-05-01 |
Hybridon Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
WO2003059381A2
(en)
|
2002-01-18 |
2003-07-24 |
Curevac Gmbh |
Immunogenic preparations and vaccines on the basis of mrna
|
CA2474709A1
(en)
|
2002-02-04 |
2003-08-14 |
Biomira, Inc. |
Immunostimulatory, covalently lipidated oligonucleotides
|
WO2003074551A2
(en)
|
2002-03-01 |
2003-09-12 |
The Administrators Of The Tulane Educational Fund |
Conjugates of therapeutic or cytotoxic agents and biologically active peptides
|
NZ573064A
(en)
|
2002-04-04 |
2011-02-25 |
Coley Pharm Gmbh |
Immunostimulatory G,U-containing oligoribonucleotides
|
US20060188990A1
(en)
|
2002-04-19 |
2006-08-24 |
Schering Aktiengesellschaft |
Novel prostate tumor-specific promoter
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
EP1393745A1
(en)
|
2002-07-29 |
2004-03-03 |
Hybridon, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends
|
WO2004058159A2
(en)
|
2002-12-23 |
2004-07-15 |
Dynavax Technologies Corporation |
Branched immunomodulatory compounds and methods of using the same
|
JP4726630B2
(ja)
|
2003-01-16 |
2011-07-20 |
イデラ ファーマシューティカルズ インコーポレイテッド |
修飾された免疫賦活性ジヌクレオチドを用いることによるオリゴヌクレオチドに基づく化合物の免疫賦活特性の調節
|
US9068234B2
(en)
*
|
2003-01-21 |
2015-06-30 |
Ptc Therapeutics, Inc. |
Methods and agents for screening for compounds capable of modulating gene expression
|
US8969543B2
(en)
|
2003-04-03 |
2015-03-03 |
Bioneer Corporation |
SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
|
WO2004092329A2
(en)
|
2003-04-08 |
2004-10-28 |
Galenica Pharmaceuticals, Inc. |
Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines
|
CA2521662A1
(en)
|
2003-04-10 |
2005-01-06 |
3M Innovative Properties Company |
Methods and compositions for enhancing immune response
|
CA2530613A1
(en)
|
2003-06-30 |
2005-01-06 |
Universite De Lausanne |
Rasgap derived peptide for selectively killing cancer cells
|
WO2005004907A1
(en)
|
2003-07-10 |
2005-01-20 |
Cytos Biotechnology Ag |
Packaged virus-like particles
|
KR101032853B1
(ko)
|
2003-08-05 |
2011-05-06 |
에이브이아이 바이오파마 인코포레이티드 |
웨스트 나일 바이러스 감염을 치료하기 위한 약학적 조성물
|
DE10335833A1
(de)
|
2003-08-05 |
2005-03-03 |
Curevac Gmbh |
Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
|
GB0321615D0
(en)
|
2003-09-15 |
2003-10-15 |
Glaxo Group Ltd |
Improvements in vaccination
|
EP1663316A2
(en)
|
2003-09-25 |
2006-06-07 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid lipophilic conjugates
|
DE10346721A1
(de)
|
2003-10-08 |
2005-05-04 |
Holger Kalthoff |
Oligonukleotide, diese enthaltende Mittel und deren Verwendung
|
US20060142227A1
(en)
|
2003-10-14 |
2006-06-29 |
Itschak Lamensdorf |
Amphiphylic peptide-PNA conjugates for the delivery of PNA through the blood brain barrier
|
US20050112139A1
(en)
|
2003-10-23 |
2005-05-26 |
Nmk Research, Llc |
Immunogenic composition and method of developing a vaccine based on factor H binding sites
|
US20050215501A1
(en)
|
2003-10-24 |
2005-09-29 |
Coley Pharmaceutical Group, Inc. |
Methods and products for enhancing epitope spreading
|
CA2549173A1
(en)
|
2003-12-08 |
2005-07-07 |
Hybridon, Inc. |
Modulation of immunostimulatory properties by small oligonucleotide-based compounds
|
CA2551094A1
(en)
|
2003-12-22 |
2005-07-14 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for identifying rna-binding proteins
|
US20050256073A1
(en)
|
2004-02-19 |
2005-11-17 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory viral RNA oligonucleotides
|
US20080113929A1
(en)
|
2004-06-08 |
2008-05-15 |
Coley Pharmaceutical Gmbh |
Abasic Oligonucleotide as Carrier Platform for Antigen and Immunostimulatory Agonist and Antagonist
|
WO2006046978A2
(en)
|
2004-06-28 |
2006-05-04 |
Argos Therapeutics, Inc. |
Cationic peptide-mediated transformation
|
DE102004035227A1
(de)
|
2004-07-21 |
2006-02-16 |
Curevac Gmbh |
mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
|
MX2007001292A
(es)
*
|
2004-08-03 |
2007-07-04 |
Geneart Ag |
Metodo para modular la expresion genica al alterar el contendido de cpg.
|
DE102004042546A1
(de)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Kombinationstherapie zur Immunstimulation
|
US20080193468A1
(en)
|
2004-09-08 |
2008-08-14 |
Children's Medical Center Corporation |
Method for Stimulating the Immune Response of Newborns
|
TW200636064A
(en)
*
|
2004-10-28 |
2006-10-16 |
Centocor Inc |
Anti-respiratory syncytial virus antibodies, antigens and uses thereof
|
KR101366482B1
(ko)
|
2004-12-27 |
2014-02-21 |
사일런스 테라퓨틱스 아게 |
코팅된 지질 복합체 및 이들의 용도
|
US20080248067A1
(en)
|
2005-04-14 |
2008-10-09 |
The University Of Queensland |
Immunomodulating Compositions and Uses Therefor
|
AU2006241149A1
(en)
|
2005-04-26 |
2006-11-02 |
Coley Pharmaceutical Gmbh |
Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
|
DE102005023170A1
(de)
|
2005-05-19 |
2006-11-23 |
Curevac Gmbh |
Optimierte Formulierung für mRNA
|
US9505867B2
(en)
|
2005-05-31 |
2016-11-29 |
Ecole Polytechmique Fédérale De Lausanne |
Triblock copolymers for cytoplasmic delivery of gene-based drugs
|
EP1764107A1
(en)
|
2005-09-14 |
2007-03-21 |
Gunther Hartmann |
Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
|
WO2007031322A1
(en)
|
2005-09-14 |
2007-03-22 |
Gunther Hartmann |
Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
|
AU2006301230A1
(en)
|
2005-10-12 |
2007-04-19 |
Cancer Research Technology Ltd. |
Methods and compositions for treating immune disorders
|
US8101741B2
(en)
|
2005-11-02 |
2012-01-24 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
US7470674B2
(en)
|
2005-11-07 |
2008-12-30 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
|
SI1957647T1
(sl)
|
2005-11-25 |
2015-04-30 |
Zoetis Belgium S.A. |
Imunostimulatorni oligoribonukleotidi
|
US9687262B2
(en)
|
2005-11-30 |
2017-06-27 |
CARDINAL HEALTH SWITZERLAND 515 GmbH |
Methods and devices for treating vulnerable plaque
|
JP2009519033A
(ja)
|
2005-12-16 |
2009-05-14 |
ディアト |
核酸を細胞に送達するための細胞貫通ペプチド結合体
|
EP1979488A4
(en)
|
2006-01-09 |
2009-05-27 |
Univ California |
IMMUNOSTIMULATORY COMBINATIONS OF TNFRSF, TLR, NLR, RHR, PURINERGIC RECEPTOR AND CYTOKINE RECEPTOR AGONISTS USED FOR VACCINES AND ANTI-TUMOR IMMUNOTHERAPY
|
DE102006007433A1
(de)
|
2006-02-17 |
2007-08-23 |
Curevac Gmbh |
Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
|
WO2007124755A1
(en)
|
2006-05-02 |
2007-11-08 |
The Antibody Project Aps |
Method for immunizing an avian species
|
AU2007280690C1
(en)
|
2006-07-31 |
2012-08-23 |
Curevac Gmbh |
Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
|
DE102006035618A1
(de)
|
2006-07-31 |
2008-02-07 |
Curevac Gmbh |
Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
|
WO2008022046A2
(en)
|
2006-08-18 |
2008-02-21 |
Nastech Pharmaceutical Company Inc. |
Dicer substrate rna peptide conjugates and methods for rna therapeutics
|
EP1911844A1
(en)
|
2006-10-10 |
2008-04-16 |
Qiagen GmbH |
Methods and kit for isolating nucleic acids
|
DE102006051516A1
(de)
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
|
DE102006061015A1
(de)
|
2006-12-22 |
2008-06-26 |
Curevac Gmbh |
Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
KR20100063048A
(ko)
|
2007-07-31 |
2010-06-10 |
더 존스 홉킨스 유니버시티 |
신생물성 또는 감염성 장애의 면역예방 또는 면역치료를 위한 폴리펩티드-핵산 접합체
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
WO2009046739A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
WO2009053700A1
(en)
|
2007-10-23 |
2009-04-30 |
Cancer Research Technology Limited |
Modification of nucleic acid-containing biological entities
|
WO2009086640A1
(en)
|
2008-01-10 |
2009-07-16 |
Nventa Biopharmaceuticals Corporation |
Adjuvant compositions comprising poly-ic and a cationic polymer
|
EP2548960B1
(en)
*
|
2008-01-31 |
2018-01-31 |
CureVac AG |
Nucleic acids comprising formula (nugixmgnv)a and derivatives thereof as an immunostimulating agents/adjuvant
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
ES2872377T3
(es)
|
2008-05-26 |
2021-11-02 |
Univ Zuerich |
Nanopartículas de protamina/ARN para inmunoestimulación
|
KR20110074850A
(ko)
|
2008-08-25 |
2011-07-04 |
앰플리뮨, 인크. |
Pd-1 길항제 및 그의 사용 방법
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
AU2008365111B2
(en)
|
2008-12-11 |
2013-08-22 |
Psioxus Therapeutics Limited |
Modification of nucleic acid vectors with polymers comprising charged quaternary amino groups
|
WO2010088927A1
(en)
|
2009-02-09 |
2010-08-12 |
Curevac Gmbh |
Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
|
WO2011011631A2
(en)
|
2009-07-22 |
2011-01-27 |
Samuel Zalipsky |
Nucleic acid delivery vehicles
|
US20120258104A1
(en)
|
2009-07-22 |
2012-10-11 |
Cenix Bioscience Gmbh |
Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
WO2011069528A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Lyophilization of nucleic acids in lactate-containing solutions
|
EP2387999A1
(en)
|
2010-05-21 |
2011-11-23 |
CureVac GmbH |
Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
|
US20130121998A1
(en)
|
2010-06-16 |
2013-05-16 |
Myra A. Lipes |
Diagnosis of Myocardial Autoimmunity in Heart Disease
|
SG186706A1
(en)
|
2010-07-30 |
2013-02-28 |
Curevac Gmbh |
Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
US20120064110A1
(en)
|
2010-08-20 |
2012-03-15 |
Selecta Biosciences, Inc. |
Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus hemagglutinin
|
WO2012037078A2
(en)
*
|
2010-09-14 |
2012-03-22 |
Stc.Unm |
Immunogenic respiratory syncytial virus glycoprotein-containing vlps and related compositions, constructs, and therapeutic methods
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
US9763891B2
(en)
|
2011-07-22 |
2017-09-19 |
The General Hospital Corporation |
Therapeutic nanoparticles and methods of use thereof
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
EP2623121A1
(en)
|
2012-01-31 |
2013-08-07 |
Bayer Innovation GmbH |
Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
US9890391B2
(en)
|
2012-03-27 |
2018-02-13 |
Curevac Ag |
RNA vector with an open reading frame, an albumin 3′-UTR, and a histone stem loop
|
ES2654205T3
(es)
|
2012-03-27 |
2018-02-12 |
Curevac Ag |
Moléculas artificiales de ácido nucleico para la expresión mejorada de proteínas o péptidos
|
CN108929880A
(zh)
|
2012-03-27 |
2018-12-04 |
库瑞瓦格股份公司 |
包含5′toputr的人工核酸分子
|
ES2719598T3
(es)
|
2012-05-25 |
2019-07-11 |
Curevac Ag |
Inmovilización reversible y/o liberación controlada de ácidos nucleicos contenidos en nanopartículas mediante revestimientos poliméricos (biodegradables)
|
BR112015018989B1
(pt)
|
2013-02-22 |
2023-11-14 |
Curevac Ag |
Combinação de vacina/inibidor da via de pd-1, inibidor da via de pd-1 e vacina de rna
|
WO2015024666A1
(en)
|
2013-08-21 |
2015-02-26 |
Curevac Gmbh |
Composition and vaccine for treating lung cancer
|
CA2915730A1
(en)
|
2013-08-21 |
2015-02-26 |
Karl-Josef Kallen |
A combination rsv/influenza a vaccine
|
RU2016109938A
(ru)
|
2013-08-21 |
2017-09-26 |
Куревак Аг |
Композиция и вакцина для лечения рака предстательной железы
|
WO2015024667A1
(en)
|
2013-08-21 |
2015-02-26 |
Curevac Gmbh |
Method for increasing expression of rna-encoded proteins
|
AU2014310934B2
(en)
|
2013-08-21 |
2019-09-12 |
CureVac SE |
Respiratory syncytial virus (RSV) vaccine
|
BR112016001192A2
(pt)
|
2013-08-21 |
2017-08-29 |
Curevac Ag |
Vacina contra a raiva
|
CA2925021A1
(en)
|
2013-11-01 |
2015-05-07 |
Curevac Ag |
Modified rna with decreased immunostimulatory properties
|
SG10201805660WA
(en)
|
2013-12-30 |
2018-08-30 |
Curevac Ag |
Methods for rna analysis
|
US11254951B2
(en)
|
2014-12-30 |
2022-02-22 |
Curevac Ag |
Artificial nucleic acid molecules
|
WO2015101415A1
(en)
|
2013-12-30 |
2015-07-09 |
Curevac Gmbh |
Artificial nucleic acid molecules
|
BR112016014462A2
(pt)
|
2013-12-30 |
2017-10-24 |
Curevac Ag |
moléculas de ácido nucleico artificiais
|
US10307472B2
(en)
|
2014-03-12 |
2019-06-04 |
Curevac Ag |
Combination of vaccination and OX40 agonists
|
WO2015149944A2
(en)
|
2014-04-01 |
2015-10-08 |
Curevac Gmbh |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
US10837039B2
(en)
|
2014-06-10 |
2020-11-17 |
Curevac Real Estate Gmbh |
Methods and means for enhancing RNA production
|
ES2946969T3
(es)
|
2014-12-12 |
2023-07-28 |
CureVac SE |
Moléculas de ácido nucleico artificiales para una expresión proteica mejorada
|
EP3233113A1
(en)
|
2014-12-16 |
2017-10-25 |
CureVac AG |
Ebolavirus and marburgvirus vaccines
|
RU2757675C2
(ru)
|
2014-12-30 |
2021-10-20 |
Куревак Аг |
Молекулы новых искусственных нуклеиновых кислот
|
WO2016165825A1
(en)
|
2015-04-13 |
2016-10-20 |
Curevac Ag |
Method for producing rna compositions
|
SG11201707663SA
(en)
|
2015-04-17 |
2017-11-29 |
Curevac Ag |
Lyophilization of rna
|
ES2746340T3
(es)
|
2015-04-22 |
2020-03-05 |
Curevac Ag |
Composición que contiene ARN para el tratamiento de enfermedades tumorales
|
CN108064307A
(zh)
|
2015-04-30 |
2018-05-22 |
库瑞瓦格股份公司 |
使用固定化的限制酶进行体外转录的方法
|
EP3289101B1
(en)
|
2015-04-30 |
2021-06-23 |
CureVac AG |
Immobilized poly(n)polymerase
|
WO2016180430A1
(en)
|
2015-05-08 |
2016-11-17 |
Curevac Ag |
Method for producing rna
|
ES2875589T3
(es)
|
2015-05-15 |
2021-11-10 |
Curevac Ag |
Regímenes de sensibilización-refuerzo que implican la administración de al menos un constructo de ARNm
|
EP3928800A3
(en)
|
2015-05-20 |
2022-03-23 |
CureVac AG |
Dry powder composition comprising long-chain rna
|
US10517827B2
(en)
|
2015-05-20 |
2019-12-31 |
Curevac Ag |
Dry powder composition comprising long-chain RNA
|
WO2016193206A1
(en)
|
2015-05-29 |
2016-12-08 |
Curevac Ag |
A method for producing and purifying rna, comprising at least one step of tangential flow filtration
|
US11608513B2
(en)
|
2015-05-29 |
2023-03-21 |
CureVac SE |
Method for adding cap structures to RNA using immobilized enzymes
|
EP3310384A1
(en)
|
2015-06-17 |
2018-04-25 |
CureVac AG |
Vaccine composition
|
EP3317424B1
(en)
|
2015-07-01 |
2023-09-06 |
CureVac Manufacturing GmbH |
Method for analysis of an rna molecule
|
WO2017009376A1
(en)
|
2015-07-13 |
2017-01-19 |
Curevac Ag |
Method of producing rna from circular dna and corresponding template dna
|
WO2017021546A1
(en)
|
2015-08-05 |
2017-02-09 |
Curevac Ag |
Epidermal mrna vaccine
|
EP3699288A1
(en)
|
2015-08-07 |
2020-08-26 |
CureVac AG |
Process for the in vivo production of rna in a host cell
|
CN116064623A
(zh)
|
2015-08-10 |
2023-05-05 |
库瑞瓦格制造业有限公司 |
增加环状dna分子复制的方法
|
AU2016316439B2
(en)
|
2015-08-28 |
2022-02-24 |
CureVac SE |
Artificial nucleic acid molecules
|
WO2017064146A1
(en)
|
2015-10-12 |
2017-04-20 |
Curevac Ag |
Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
|
EP3373965A1
(en)
|
2015-11-09 |
2018-09-19 |
CureVac AG |
Rotavirus vaccines
|
US20180312545A1
(en)
|
2015-11-09 |
2018-11-01 |
Curevac Ag |
Optimized nucleic acid molecules
|
US20180371392A1
(en)
|
2015-12-21 |
2018-12-27 |
Curevac Ag |
Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
|
CN108778308A
(zh)
|
2015-12-22 |
2018-11-09 |
库瑞瓦格股份公司 |
生产rna分子组合物的方法
|
WO2017109161A1
(en)
|
2015-12-23 |
2017-06-29 |
Curevac Ag |
Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
EP3414340B1
(en)
|
2016-02-12 |
2023-08-09 |
CureVac SE |
Method for analyzing rna
|
US20190049414A1
(en)
|
2016-02-15 |
2019-02-14 |
Curevac Ag |
Method for analyzing by-products of rna in vitro transcription
|
SG10201913630YA
(en)
|
2016-02-17 |
2020-03-30 |
Curevac Ag |
Zika virus vaccine
|
EP3423595A1
(en)
|
2016-03-03 |
2019-01-09 |
CureVac AG |
Rna analysis by total hydrolysis
|
WO2017162297A1
(en)
|
2016-03-24 |
2017-09-28 |
Curevac Ag |
Immobilized inorganic pyrophosphatase (ppase)
|
EP3777881A1
(en)
|
2016-04-22 |
2021-02-17 |
CureVac AG |
Rna encoding a tumor antigen
|
US11596699B2
(en)
|
2016-04-29 |
2023-03-07 |
CureVac SE |
RNA encoding an antibody
|
WO2017191258A1
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Influenza mrna vaccines
|
WO2017191274A2
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Rna encoding a therapeutic protein
|
WO2017191264A1
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Nucleic acid molecules and uses thereof
|
US20180126003A1
(en)
|
2016-05-04 |
2018-05-10 |
Curevac Ag |
New targets for rna therapeutics
|
US20190194760A1
(en)
|
2016-05-25 |
2019-06-27 |
Curevac Ag |
Novel biomarkers
|
CA3023174A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
US20190336608A1
(en)
|
2016-06-09 |
2019-11-07 |
Curevac Ag |
Cationic carriers for nucleic acid delivery
|
WO2017212008A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
WO2017212006A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
WO2018033254A2
(en)
|
2016-08-19 |
2018-02-22 |
Curevac Ag |
Rna for cancer therapy
|
AU2017350488B2
(en)
|
2016-10-26 |
2022-06-23 |
Acuitas Therapeutics Inc. |
Lipid nanoparticle mRNA vaccines
|
WO2018096179A1
(en)
|
2016-11-28 |
2018-05-31 |
Curevac Ag |
Method for purifying rna
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
CN110582304A
(zh)
|
2016-12-08 |
2019-12-17 |
库尔维科公司 |
用于治疗或预防肝脏疾病的rna
|
US11524066B2
(en)
|
2016-12-23 |
2022-12-13 |
CureVac SE |
Henipavirus vaccine
|
US11464847B2
(en)
|
2016-12-23 |
2022-10-11 |
Curevac Ag |
Lassa virus vaccine
|
US11141476B2
(en)
|
2016-12-23 |
2021-10-12 |
Curevac Ag |
MERS coronavirus vaccine
|
CN110392577A
(zh)
|
2017-03-17 |
2019-10-29 |
库尔维科公司 |
用于组合抗癌疗法的rna疫苗和免疫检查点抑制剂
|
AU2018240515A1
(en)
|
2017-03-24 |
2019-08-01 |
CureVac SE |
Nucleic acids encoding CRISPR-associated proteins and uses thereof
|
CN111328287A
(zh)
|
2017-07-04 |
2020-06-23 |
库瑞瓦格股份公司 |
新型核酸分子
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
RU2020117848A
(ru)
|
2017-11-08 |
2021-12-08 |
Куревак Аг |
Адаптиция последовательности phk
|
WO2019115635A1
(en)
|
2017-12-13 |
2019-06-20 |
Curevac Ag |
Flavivirus vaccine
|
US11525158B2
(en)
|
2017-12-21 |
2022-12-13 |
CureVac SE |
Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA
|
US20210361761A1
(en)
|
2018-04-05 |
2021-11-25 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
CA3091558A1
(en)
|
2018-04-17 |
2019-10-24 |
Curevac Ag |
Novel rsv rna molecules and compositions for vaccination
|
WO2020002525A1
(en)
|
2018-06-27 |
2020-01-02 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
RU2765877C1
(ru)
|
2018-06-28 |
2022-02-04 |
Кьюрвак Аг |
Биореактор для транскрипции рнк in vitro
|
EP3897702A2
(en)
|
2018-12-21 |
2021-10-27 |
CureVac AG |
Rna for malaria vaccines
|
WO2020127959A1
(en)
|
2018-12-21 |
2020-06-25 |
Curevac Ag |
Methods for rna analysis
|
US11241493B2
(en)
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|
US11576966B2
(en)
|
2020-02-04 |
2023-02-14 |
CureVac SE |
Coronavirus vaccine
|